Terms ending in 2043
Every in-force patent on Genmab A/S's record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,398,214 | Binding Agents Binding to Epcam and CD137 In force · High confidence | BioNTech SE | In force | High confidence | |
| US 11,932,693 | Monoclonal Antibodies Directed Against Programmed DEATH-1 Protein and Their Use in Medicine In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,692,320 | Bispecific Antibodies Against CD3 and CD20 In force · Medium confidence | Genmab A/S | In force | Medium confidence | |
| US 12,674,001 | Method of Treating Cancer by Administering an Antibody Which Binds to 5T4 In force · High confidence | Genmab A/S | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Genmab A/S.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.